Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 14/20 | 0.71 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.52 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.52 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | PRNP | P04156 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16333144 | 0.87 | NOTUM (0.69) | NOTUMHPGDKDM4ECSNK2A2CSNK2B | |
| SCHEMBL16333408 | 0.84 | NOTUM (0.71) | NOTUMHPGDKDM4ECSNK2A2CSNK2B | |
| SCHEMBL16333328 | 0.83 | NOTUM (1.00) | NOTUMHPGDKDM4ECSNK2A2CSNK2B | |
| SCHEMBL438085 | 0.82 | NOTUM (0.77) | NOTUMHPGDKDM4EMEN1KMT2A | |
| SCHEMBL438065 | 0.81 | NOTUM (0.77) | NOTUMHPGDKDM4ECSNK2A2CSNK2B | |
| SCHEMBL438060 | 0.81 | NOTUM (0.77) | NOTUMCSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL440651 | 0.76 | NOTUM (0.77) | NOTUMHPGDKDM4ECSNK2A2CSNK2B | |
| SCHEMBL439137 | 0.75 | NOTUM (0.76) | NOTUMHPGDKDM4ECSNK2A2CSNK2B | |
| SCHEMBL16333308 | 0.74 | NOTUM (0.76) | NOTUMHPGDKDM4EMEN1KMT2A | |
| SCHEMBL8234971 | 0.72 | NOTUM (0.63) | NOTUMHPGDKDM4ECSNK2A2CSNK2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2616471-B1 | INHIBITORS OF NOTUM PECTINACETYLESTERASE AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS INC (US) | 2014-12-31 | — | — | EP | disclosed |
| EP-2616471-B1 | INHIBITORS OF NOTUM PECTINACETYLESTERASE AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS INC (US) | 2014-12-31 | — | — | EP | disclosed |
| US-20140288071-A1 | INHIBITORS OF NOTUM PECTINACETYLESTERASE AND METHODS OF THEIR USE | BARBOSA JOSEPH (US) | 2014-09-25 | — | — | US | disclosed |
| US-20140288071-A1 | INHIBITORS OF NOTUM PECTINACETYLESTERASE AND METHODS OF THEIR USE | BARBOSA JOSEPH (US) | 2014-09-25 | — | — | US | disclosed |
| US-20140288071-A1 | INHIBITORS OF NOTUM PECTINACETYLESTERASE AND METHODS OF THEIR USE | BARBOSA JOSEPH (US) | 2014-09-25 | — | — | US | disclosed |
| EP-2616471-A1 | INHIBITORS OF NOTUM PECTINACETYLESTERASE AND METHODS OF THEIR USE | Lexicon Pharmaceuticals, Inc. (US) | 2013-07-24 | — | — | EP | disclosed |
| WO-2012037141-A1 | INHIBITORS OF NOTUM PECTINACETYLESTERASE AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
| WO-2012037141-A1 | INHIBITORS OF NOTUM PECTINACETYLESTERASE AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
| US-20120065200-A1 | INHIBITORS OF NOTUM PECTINACETYLESTERASE AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. | 2012-03-15 | — | — | US | disclosed |
| US-20120065200-A1 | INHIBITORS OF NOTUM PECTINACETYLESTERASE AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. | 2012-03-15 | — | — | US | disclosed |
| US-20120065200-A1 | INHIBITORS OF NOTUM PECTINACETYLESTERASE AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065200-A1 | INHIBITORS OF NOTUM PECTINACETYLESTERASE AND METHODS OF THEIR USE | NOTUM, GLA, CES1 | NOTUM 1/4885HPGD 1208/4885KDM4E 406/4885 |
| US-20140288071-A1 | INHIBITORS OF NOTUM PECTINACETYLESTERASE AND METHODS OF THEIR USE | NOTUM, GLA, CES1 | NOTUM 1/4885HPGD 1208/4885KDM4E 406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.